[Use of a new water-soluble aldosterone-antagonist in surgery. Early clinical results].
A new i.v., water-soluble aldosterone antagonist (potassium canrenoate) was employed for the first time in a series of patients operated for various forms of abdominal disease. The pharmacological and clinical effects of the drug were constantly reproduced and a marked anti-aldosterone activity was noted. The drug is felt to be specifically indicated in the management of secondary hyperaldosteronism typical of the immediate postoperative period.
D000328:Adult; D000368:Aged; D001660:Biliary Tract Diseases / Q000601:surgery; D005260:Female; D005767:Gastrointestinal Diseases / Q000601:surgery; D005770:Gastrointestinal Neoplasms / Q000601:surgery; D006801:Humans; D006929:Hyperaldosteronism / Q000188:drug therapy*; D007813:Laparotomy; D008297:Male; D008875:Middle Aged; D000451:Mineralocorticoid Receptor Antagonists; D011183:Postoperative Complications / Q000188:drug therapy*; D013148:Spironolactone / Q000627:therapeutic use*
D000451:Mineralocorticoid Receptor Antagonists; D013148:Spironolactone
L'impiego di un nuovo antagonista idro-solubile dell'aldosterone in campo chirurgico. Primi risultati clinici